Bendamustine HCl Injection, 100mg/4mL (25mg/mL), One 4 mL Multiple-Dose Vial, Rx only, Manufactur...

FDA Recall #D-1103-2023 — Class III — August 14, 2023

Recall #D-1103-2023 Date: August 14, 2023 Classification: Class III Status: Completed

Product Description

Bendamustine HCl Injection, 100mg/4mL (25mg/mL), One 4 mL Multiple-Dose Vial, Rx only, Manufactured for Baxter Healthcare Corporation, Deerfield, IL 60015, NDC 10019-079-01.

Reason for Recall

Labeling: Missing Label; customer complaint received that labels were partially or completely peeled off injection vial.

Recalling Firm

Baxter Healthcare Corporation — Deerfield, IL

Classification

Class III — Not likely to cause adverse health consequences.

Product Type

Drugs

Product Quantity

13,502 vials

Distribution

Nationwide in the U.S.A.

Code Information

Lots: 3A004A, 3A004B, Exp 12/31/2024; 3B005A, Exp 1/31/2025

Status

Completed

Voluntary / Mandated

Voluntary: Firm initiated